MedTrace Logo

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender

NCT01687309 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-05-25

No results posted yet for this study

Summary

A study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and repeat doses of 800 mg GSK2586184 in healthy subjects.

Conditions

Interventions

DRUG

GSK2586184 800mg single and repeat dose

GSK2586184 800mg single dose and then twice daily dosing for 13 days

DRUG

Placebo-to-match GSK2586184

Placebo-to-match GSK2586184

OTHER

GSK2586184 single dose taken with food

GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast

OTHER

GSK2586184 single dose taken without food

GSK2586184 single dose taken in a fasted state

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01687309 on ClinicalTrials.gov